These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1989642)

  • 1. Platelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-methyl and SRI 62-834 in HL-60 promyelocytic leukaemia cells.
    Workman P; Donaldson J; Lohmeyer M
    Biochem Pharmacol; 1991 Jan; 41(2):319-22. PubMed ID: 1989642
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells.
    Dive C; Watson JV; Workman P
    Cancer Res; 1991 Feb; 51(3):799-806. PubMed ID: 1988120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of enantio-selectivity in the in vitro antitumour cytotoxicity and membrane-damaging activity of ether lipid SRI 62-834: further evidence for a non-receptor-mediated mechanism of action.
    Lohmeyer M; Workman P
    Biochem Pharmacol; 1992 Aug; 44(4):819-23. PubMed ID: 1510728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Platelet-activating factor (PAF) antagonists].
    Terasawa M
    Tanpakushitsu Kakusan Koso; 1991 Feb; 36(3):379-87. PubMed ID: 1850862
    [No Abstract]   [Full Text] [Related]  

  • 5. Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells.
    Cellai C; Laurenzana A; Vannucchi AM; Della Malva N; Bianchi L; Paoletti F
    FASEB J; 2002 May; 16(7):733-5. PubMed ID: 11923217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth arrest vs direct cytotoxicity and the importance of molecular structure for the in vitro anti-tumour activity of ether lipids.
    Lohmeyer M; Workman P
    Br J Cancer; 1995 Aug; 72(2):277-86. PubMed ID: 7640206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism.
    Le Blanc K; Samuelsson J; Brohult J; Berg A; Palmblad J
    Biochem Pharmacol; 1995 May; 49(11):1577-82. PubMed ID: 7786298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An antagonist to platelet activating factor counteracts the tumoricidal action of alkyl lysophospholipids.
    Bazill GW; Dexter TM
    Biochem Pharmacol; 1989 Jan; 38(2):374-7. PubMed ID: 2536543
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of neutrophil respiratory burst and degranulation responses to platelet-activating factor by antagonists WEB 2086, CV 6209 and CV 3988.
    Bates EJ; Harvey DP; Ferrante A
    Int Arch Allergy Immunol; 1992; 97(1):50-6. PubMed ID: 1582698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary vascular reactivity: effect of PAF and PAF antagonists.
    Chen CR; Voelkel NF; Chang SW
    J Appl Physiol (1985); 1992 Nov; 73(5):1762-9. PubMed ID: 1474049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of neutrophil and eosinophil chemotactic responses to PAF by the PAF-antagonists WEB-2086, L-652,731, and SRI-63441.
    Håkansson L; Venge P
    J Leukoc Biol; 1990 May; 47(5):449-56. PubMed ID: 2335754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells.
    Bazill GW; Dexter TM
    Cancer Res; 1990 Dec; 50(23):7505-12. PubMed ID: 2253199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
    Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
    J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of synthetic alkylphospholipids with or without PAF activity.
    Kudo I; Nojima S; Chang HW; Yanoshita R; Hayashi H; Kondo E; Nomura H; Inoue K
    Lipids; 1987 Nov; 22(11):862-7. PubMed ID: 3444379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of ether lipid 1-O-octadecyl-2-O-methoxy-rac-glycero-3-phosphocholine and its analogues platelet activating factor and carbamyl-platelet activating factor on the biosynthesis of interleukin-6 in human thymic epithelial cells cultivated in vitro.
    Cardile V; Mascarucci P; De Simoni MG; Jiang X; Bindoni M
    Cytokine; 1996 Sep; 8(9):698-701. PubMed ID: 8932980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A flow cytometric assay reveals an enhancement of phagocytosis by platelet activating factor in murine peritoneal macrophages.
    Ichinose M; Hara N; Sawada M; Maeno T
    Cell Immunol; 1994 Jul; 156(2):508-18. PubMed ID: 8025959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological analysis of neutrophil chemotactic factor production by leucocytes and roles of PAF in allergic inflammation in rats.
    Watanabe M; Arakida Y; Tanabe J; Sugidachi A; Hirasawa N; Mue S; Ohuchi K
    Br J Pharmacol; 1994 Jan; 111(1):123-30. PubMed ID: 8012688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-activating factor (PAF) receptor-mediated calcium mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells: studies with BN50739, a new PAF antagonist.
    Yue TL; Gleason MM; Gu JL; Lysko PG; Hallenbeck J; Feuerstein G
    J Pharmacol Exp Ther; 1991 Apr; 257(1):374-81. PubMed ID: 1850473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissociation of the effects of the antitumour ether lipid ET-18-OCH3 on cytosolic calcium and on apoptosis.
    Alonso MT; Gajate C; Mollinedo F; Modolell M; Alvarez J; García-Sancho J
    Br J Pharmacol; 1997 Aug; 121(7):1364-8. PubMed ID: 9257915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
    Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
    Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.